טוען...
Clinical implications of mismatch repair deficiency in prostate cancer
Immune checkpoint blockade holds great promise in the treatment of solid tumors but has not yet been approved for use in advanced prostate cancer. This is largely due to the relatively modest response in clinical trials in unselected patients and the lack of available biomarkers to predict clinical...
שמור ב:
| הוצא לאור ב: | Future Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Future Medicine Ltd
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6714067/ https://ncbi.nlm.nih.gov/pubmed/31237441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0068 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|